MorphoSys AG and Incyte Sign Global Collaboration and License Agreement for Tafasitamab Conference Call Transcript
Ladies and gentlemen, welcome to the conference call of MorphoSys and Incyte. (Operator Instructions) And the conference is being recorded. (Operator Instructions)
Now I would like to turn the conference over to Sarah Fakih. Please go ahead.
Thank you. Good morning, good afternoon, and welcome to our joint conference call and webcast to discuss the announcement of our global partnership deal with Incyte which was signed yesterday evening Pacific time. My name is Sarah Fakih. I'm the Head of Corporate Communications and Investor Relations at MorphoSys.
With me on the call today are Jean-Paul Kress, our Chief Executive Officer; and Jens Holstein, our Chief Financial Officer. And we are very pleased to be joined by Hervé Hoppenot, the CEO of Incyte, Christiana Stamoulis, Incyte CFO; and Mike Booth, Incyte Head of Investor Relations.
Before we start, I would like to remind you that during this conference call, we may discuss certain forward-looking statements,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
